CA2318434A1 - Chimeres et conjugues polypeptidiques thrombogenes presentant une activite dependant de l'association avec l'endothelium vasculaire tumoral - Google Patents

Chimeres et conjugues polypeptidiques thrombogenes presentant une activite dependant de l'association avec l'endothelium vasculaire tumoral Download PDF

Info

Publication number
CA2318434A1
CA2318434A1 CA002318434A CA2318434A CA2318434A1 CA 2318434 A1 CA2318434 A1 CA 2318434A1 CA 002318434 A CA002318434 A CA 002318434A CA 2318434 A CA2318434 A CA 2318434A CA 2318434 A1 CA2318434 A1 CA 2318434A1
Authority
CA
Canada
Prior art keywords
context
functional entity
dependent functional
substructure
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002318434A
Other languages
English (en)
Inventor
L.L. Houston
Craig D. Dickinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NuVas LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2318434A1 publication Critical patent/CA2318434A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des polypeptides et des conjugués chimères initiateurs de thrombsose, un exemple de ces polypeptides et conjugués étant donné dans la Figure 1. L'invention concerne également des compositions renfermant ces polypeptides et ces conjugués, et des produits de recombinaison d'acide nucléique codant ces derniers. Au moins un constituant d'une chimère ou d'un conjugué est spécifique à une ou plusieurs caractéristiques externes de l'endothélium vasculaire des vaisseaux entretenant une tumeur, et au moins un constituant thrombosant est sensiblement inactif si non associé à cet endothélium vasculaire tumoral, ce qui permet une destruction ciblée des tumeurs solides chez un animal.
CA002318434A 1997-12-23 1998-12-22 Chimeres et conjugues polypeptidiques thrombogenes presentant une activite dependant de l'association avec l'endothelium vasculaire tumoral Abandoned CA2318434A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99674497A 1997-12-23 1997-12-23
US08/996,744 1997-12-23
PCT/US1998/027498 WO1999032143A1 (fr) 1997-12-23 1998-12-22 Chimeres et conjugues polypeptidiques thrombogenes presentant une activite dependant de l'association avec l'endothelium vasculaire tumoral

Publications (1)

Publication Number Publication Date
CA2318434A1 true CA2318434A1 (fr) 1999-07-01

Family

ID=25543254

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002318434A Abandoned CA2318434A1 (fr) 1997-12-23 1998-12-22 Chimeres et conjugues polypeptidiques thrombogenes presentant une activite dependant de l'association avec l'endothelium vasculaire tumoral

Country Status (4)

Country Link
EP (1) EP1041999A1 (fr)
AU (1) AU2094199A (fr)
CA (1) CA2318434A1 (fr)
WO (1) WO1999032143A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576610B1 (en) 1999-10-04 2003-06-10 Nuvas, Llc Use of a context-dependent functional entity to enhance the efficacy of an agent
DE60115422T2 (de) * 2000-05-10 2006-08-17 Novo Nordisk Health Care Ag PHARMAZEUTISCHE ZUSAMMENSETZUNG ENTHALTEND EINEN FAKTOR VIIa UND EINEN TFPI-INHIBITOR
WO2002020813A2 (fr) 2000-09-05 2002-03-14 Karolinska Innovations Ab Materiaux et procedes concernant des inhibiteurs de croissance cellulaire endotheliale
EP1443954B1 (fr) * 2001-10-26 2010-11-24 The Scripps Research Institute Thrombose cible par de polypeptides du facteur tissulaire
US7393833B2 (en) * 2005-03-09 2008-07-01 The Board Of Regents Of The University Of Oklahoma Chimeric proteins with phosphatidylserine binding domains

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5433955A (en) * 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature

Also Published As

Publication number Publication date
WO1999032143A1 (fr) 1999-07-01
EP1041999A1 (fr) 2000-10-11
AU2094199A (en) 1999-07-12

Similar Documents

Publication Publication Date Title
EP1107989B1 (fr) Expression et exportation d'angiostatine et d'endostatine sous forme d'immunofusines
JP5952847B2 (ja) 成長因子と結合する融合タンパク質
KR101943420B1 (ko) 변형된 혈관활성 장 펩티드
US6423513B1 (en) Polynucleotides encoding protease-activatable pseudomonas exotoxin a-like proproteins
JP6676551B2 (ja) 改変フォンウィルブランド因子
JP6755318B2 (ja) 突然変異フォン・ヴィレブランド因子
RU2620072C2 (ru) ПРОИЗВОДНЫЕ ФАКТОРОВ СВЕРТЫВАНИЯ КРОВИ VII И VIIa, КОНЪЮГАТЫ И КОМПЛЕКСЫ, СОДЕРЖАЩИЕ ИХ, И ИХ ПРИМЕНЕНИЕ
CA2649199C (fr) Methode destinee a augmenter le taux de recuperation in vivo de polypeptides therapeutiques
JPH07508420A (ja) 肝細胞成長因子変異体
US20080193441A1 (en) Homogeneous Preparations of Chimeric Protein
JPH0592999A (ja) 膀胱癌細胞の処置法
KR20070036057A (ko) 코브라 베놈 인자-유사 기능을 갖는 사람 보체 ｃ3 유도체
JPWO2005089070A1 (ja) トロンビン誘導体、およびそれを含有する医薬組成物
CA2318434A1 (fr) Chimeres et conjugues polypeptidiques thrombogenes presentant une activite dependant de l'association avec l'endothelium vasculaire tumoral
KR0169729B1 (ko) 하이브리드 단백질, 이의 생산방법 및 이를 함유하는 약제학적 조성물
JP2000504218A (ja) リガンド指令酵素プロドラッグ療法
US11028144B2 (en) Soluble glycoprotein V for treating thrombotic diseases

Legal Events

Date Code Title Description
FZDE Dead